FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit

Area of Science:

• Orthopedics and Musculoskeletal Diseases
• Drug Development and Therapeutics
• Biomarkers and Clinical Endpoints

Background:

• Osteoarthritis (OA) presents significant challenges for therapeutic development, evidenced by numerous clinical trial failures.
• The slow onset and long duration required for OA clinical trials complicate the demonstration of intervention efficacy.

Purpose of the Study:

• To summarize a workshop focused on the current state of osteoarthritis science.
• To identify knowledge gaps in OA research and development.
• To examine developmental and regulatory hurdles for OA therapeutics.

Main Methods:

• A virtual workshop was convened on June 22nd, 2021.
• Presentations by selected speakers covered key aspects of OA drug development.
• Discussions included current therapy assessment, biomarker utility, and disease progression evaluation.

Main Results:

• Current approaches to OA therapy assessment were reviewed.
• The role of biomarkers in osteoarthritis drug development was discussed.
• Methods for assessing disease progression and long-term benefit were presented.

Conclusions:

• Osteoarthritis drug development is hindered by disease complexity and trial requirements.
• Continued development and validation of clinical endpoints are crucial.
• Collaboration among academia, industry, regulatory bodies, and patients is essential for advancing OA therapeutics.